Armistice Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Armistice Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150,000	Closed	-$6.67M	–	241
2022 Q2	$6.67M	Sell	150,000 -74,000	-33%	-$3.4M	0.12%	92
2022 Q1	$11.1M	Buy	+224,000	New	+$10.8M	0.21%	72
2021 Q2	–	Sell	-192,000	Closed	-$8.01M	–	145
2021 Q1	$8.01M	Sell	192,000 -172,000	-47%	-$7.99M	0.18%	83
2020 Q4	$17M	Sell	364,000 -308,000	-46%	-$14.4M	0.58%	53
2020 Q3	$28.5M	Buy	672,000 +390,000	+138%	+$17.1M	1.04%	37
2020 Q2	$13.5M	Buy	+282,000	New	+$14.1M	0.59%	58

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Armistice Capital's EGRX Position: Q3 2022 in Review

Armistice Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 150,000 shares — an estimated $6.67M sold.

Armistice Capital first reported a position in EGRX in Q2 2020 and held it in 6 quarters. The position peaked at $28.5M in Q3 2020. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Armistice Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Armistice Capital sold 150,000 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $6.67M.
Armistice Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 6 quarters.
Armistice Capital's Eagle Pharmaceuticals, Inc. position peaked at $28.5M in Q3 2020.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.